BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 29135030)

  • 1. Hepatitis C Virus Clearance in Older Adults.
    Ippolito AM; Iacobellis A; Milella M; Conti F; Messina V; Valvano MR; Niro GA; Morisco F; Barone M; Termite AP; Brancaccio G; Andriulli A
    J Am Geriatr Soc; 2018 Jan; 66(1):85-91. PubMed ID: 29135030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.
    Calvaruso V; Cabibbo G; Cacciola I; Petta S; Madonia S; Bellia A; Tinè F; Distefano M; Licata A; Giannitrapani L; Prestileo T; Mazzola G; Di Rosolini MA; Larocca L; Bertino G; Digiacomo A; Benanti F; Guarneri L; Averna A; Iacobello C; Magro A; Scalisi I; Cartabellotta F; Savalli F; Barbara M; Davì A; Russello M; Scifo G; Squadrito G; Cammà C; Raimondo G; Craxì A; Di Marco V;
    Gastroenterology; 2018 Aug; 155(2):411-421.e4. PubMed ID: 29655836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
    Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
    J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    Conti F; Brillanti S; Buonfiglioli F; Vukotic R; Morelli MC; Lalanne C; Massari M; Foschi FG; Bernabucci V; Serio I; Prati GM; Negri E; Badia L; Caraceni P; Muratori P; Vitale G; Porro A; Morotti M; Mazzella G; Andreone P
    J Viral Hepat; 2017 Jun; 24(6):454-463. PubMed ID: 27976461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
    El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
    Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of functional benefit of hepatitis C therapy in a 'real-life' cohort.
    Steinebrunner N; Stein K; Sandig C; Bruckner T; Stremmel W; Pathil A
    World J Gastroenterol; 2018 Feb; 24(7):852-861. PubMed ID: 29467555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study.
    Ippolito AM; Milella M; Messina V; Conti F; Cozzolongo R; Morisco F; Brancaccio G; Barone M; Santantonio T; Masetti C; Tundo P; Smedile A; Carretta V; Gatti P; Termite AP; Valvano MR; Bruno G; Fabrizio C; Andreone P; Zappimbulso M; Gaeta GB; Napoli N; Fontanella L; Lauletta G; Cuccorese G; Metrangolo A; Francavilla R; Ciracì E; Rizzo S; Andriulli A
    Dig Liver Dis; 2017 Sep; 49(9):1022-1028. PubMed ID: 28487083
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study.
    Janczewska E; Kołek MF; Lorenc B; Klapaczyński J; Tudrujek-Zdunek M; Sitko M; Mazur W; Zarębska-Michaluk D; Buczyńska I; Dybowska D; Czauż-Andrzejuk A; Berak H; Krygier R; Jaroszewicz J; Citko J; Piekarska A; Dobracka B; Socha Ł; Deroń Z; Laurans Ł; Białkowska-Warzecha J; Tronina O; Adamek B; Tomasiewicz K; Simon K; Pawłowska M; Halota W; Flisiak R
    World J Gastroenterol; 2021 May; 27(18):2177-2192. PubMed ID: 34025072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus eradication by direct-acting antiviral agents improves carotid atherosclerosis in patients with severe liver fibrosis.
    Petta S; Adinolfi LE; Fracanzani AL; Rini F; Caldarella R; Calvaruso V; Cammà C; Ciaccio M; Di Marco V; Grimaudo S; Licata A; Marrone A; Nevola R; Pipitone RM; Pinto A; Rinaldi L; Torres D; Tuttolomondo A; Valenti L; Fargion S; Craxì A
    J Hepatol; 2018 Jul; 69(1):18-24. PubMed ID: 29505844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
    Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
    J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moderate Sustained Virologic Response Rates With 6-Week Combination Directly Acting Anti-Hepatitis C Virus Therapy in Patients With Advanced Liver Disease.
    Kattakuzhy S; Wilson E; Sidharthan S; Sims Z; McLaughlin M; Price A; Silk R; Gross C; Akoth E; McManus M; Emmanuel B; Shrivastava S; Tang L; Nelson A; Teferi G; Chavez J; Lam B; Mo H; Osinusi A; Polis MA; Masur H; Kohli A; Kottilil S
    Clin Infect Dis; 2016 Feb; 62(4):440-447. PubMed ID: 26503379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.
    Petta S; Rini F; Calvaruso V; Cammà C; Ciminnisi S; Di Marco V; Giannini EG; Grimaudo S; Maria Pipitone R; Craxì A
    Liver Int; 2020 Mar; 40(3):530-538. PubMed ID: 31507057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy).
    Scaglione V; Mazzitelli M; Costa C; Pisani V; Greco G; Serapide F; Lionello R; La Gamba V; Marascio N; Trecarichi EM; Torti C
    Medicina (Kaunas); 2020 Feb; 56(3):. PubMed ID: 32121135
    [No Abstract]   [Full Text] [Related]  

  • 15. Reversion of disease manifestations after HCV eradication.
    van der Meer AJ; Berenguer M
    J Hepatol; 2016 Oct; 65(1 Suppl):S95-S108. PubMed ID: 27641991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry.
    Fernández Carrillo C; Lens S; Llop E; Pascasio JM; Crespo J; Arenas J; Fernández I; Baliellas C; Carrión JA; de la Mata M; Buti M; Castells L; Albillos A; Romero M; Turnes J; Pons C; Moreno-Planas JM; Moreno-Palomares JJ; Fernández-Rodriguez C; García-Samaniego J; Prieto M; Fernández Bermejo M; Salmerón J; Badia E; Salcedo M; Herrero JI; Granados R; Blé M; Mariño Z; Calleja JL
    Hepatology; 2017 Jun; 65(6):1810-1822. PubMed ID: 28170112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Impact of Direct-Acting Antiviral Agent Therapy in HCV Cirrhosis: Critical Review.
    Fehily SR; Papaluca T; Thompson AJ
    Semin Liver Dis; 2019 Jul; 39(3):341-353. PubMed ID: 31041785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease.
    Manoj Kumar ; Nayak SL; Gupta E; Kataria A; Sarin SK
    Liver Int; 2018 Dec; 38(12):2137-2148. PubMed ID: 29676846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment.
    Kozbial K; Moser S; Al-Zoairy R; Schwarzer R; Datz C; Stauber R; Laferl H; Strasser M; Beinhardt S; Stättermayer AF; Gschwantler M; Zoller H; Maieron A; Graziadei I; Trauner M; Steindl-Munda P; Hofer H; Ferenci P
    Liver Int; 2018 Jun; 38(6):1028-1035. PubMed ID: 29136329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
    Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
    Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.